Lundbeck Articles
Lundbeck and Takeda's Brintellix shows positive results in Ph III major depression study
20 May 2013
Launch of Biotie/Lundbeck's Selincro will see a paradigm shift in alcohol addiction market
10 May 2013
Briefs: New research deals for AstraZeneca and Novo Nordisk; Lundbeck's Selincro launched in Europe
22 April 2013
Lundbeck could get $825 million in further deal with Otsuka, for Alzheimer's drug condidate
26 March 2013
ANN meeting highlights: Novartis' Gilenya, Lundbeck's Azilect, Orion's ODM-101, Biotie's tozadenant
21 March 2013
European Commission enforcement action in pharmaceutical sector following sector inquiry
31 January 2013
Patient trust in drugmakers declining, new report shows
14 January 2013
Recordati buys US portfolio of drugs from Lundbeck
17 December 2012
Biotie's Parkinson's drug tozadenant clears Phase IIb study
11 December 2012
Lundbeck beats expectations, despite Lexapro slump
7 November 2012
Good news from CHMP for Astellas, Savient, Bayer and Abbott, but not for Lundbeck and Merz
22 October 2012
Lundbeck in neurodegeneration collaboration with ImaginAb
9 October 2012
Regulatory briefs: Celgene's pomalidomide; Lundbeck's vortioxetine
21 September 2012
Resubmission of aripiprazole NDA accepted; AstraZeneca bond issue
12 September 2012
Lundbeck takes 5% stake in Biotie; amends Selincro licensing deal
7 September 2012
Lundbeck gets marketing OK for Treanda in Canada
29 August 2012
Lundbeck restructures, with 600 job cuts anticipated
17 June 2012
Lundbeck and Takeda to file for Lu AA21004 approval in USA and Europe on strong Ph III results
15 May 2012
Lundbeck buys remaining rights to desmoteplase from Paion
29 February 2012
Almirall looks to robust 2012 despite higher losses
28 February 2012
Lundbeck posts strong 2011 results but warns of flat time ahead
9 February 2012
Two UK product launches
16 January 2012
Lundbeck manufacturing cost achievements rewarded
16 January 2012
Vernalis jumps on deal with Genentech
5 January 2012
Lundbeck invests in Ossianix; debuts Onfi in USA
3 January 2012
Lundbeck divests three branded injectables to Akorn
23 December 2011
Lundbeck to pay up to $1.8B to Otsuka under global psychiatric and neuroscience products accord
11 November 2011
Lundbeck to tap China’s R&D, setting up own research center
17 October 2011
Lundbeck to expand opportunities in Canada and Latin America with Cephalon products
10 February 2011
Final appraisal from UK’s NICE backs improved treatment access for early Alzheimer’s disease; SMC negative for Nexavar
18 January 2011
Variations in Parkinson's disease treatment among prescribers in France, Germany, Italy, Spain and the UK
2 December 2010
Denmark’s Lundbeck buys rights to Merck & Co’s antipsychotic Sycrest; enters deal with Genmab
13 October 2010
UK’s NICE does about turn on Alzheimer’s drugs but unable to recommend Merck & Co/J&J’s psoriatic arthritis drug Simponi
7 October 2010
Lundbeck partner Mochida files for escitalopram approval in Japan
17 September 2010
In USA, Lundbeck wins Federal Trade Commission case over NeoProfen; Lilly wins Court action on Zyprexa
13 September 2010
Combo Alzheimer's drug that delays nursing home admission would earn higher patient share in the USA than Europe
18 February 2010
Pharmaceutical M&A deals in 2009
4 February 2010
EU action on pharma patent “pay-to-delay” settlements - a legal opinion; US FTC also to review the subject
13 January 2010
Germany’s Merz to acquire BioForm Medical for $253 milliion
5 January 2010
European Commission confirms further surprise inspections in the pharmaceutical sector
10 December 2009
Ischemic stroke continues to be a graveyard for drug development, says Decision Resources, but market will grow to $450 million in 2018
18 November 2009
Generic erosion of atypical antipsychotics will cause the bipolar disorder drug market to decline by over $1 billion through 2018
6 November 2009
Lundbeck gains US approval for Sabril
24 August 2009
Patent protection for key blockbuster depression drugs will drive growth in Europe and Japan, but not USA, says DR report
18 August 2009
Lundbeck falls 16.5% on delay for Lu AA21004
9 June 2009
Stock Commentary - Europe - week to June 1, 2009
4 June 2009
Still no FDA verdict for H Lundbeck's Serdolect
21 May 2009
Lundbeck shares driven up by higher profit
15 May 2009
Lundbeck launches ATryn in USA
7 May 2009
Elan 1st-qtr net loss widens 20% to $102.6M
27 April 2009
US Lipitor and Lexapro cost cut by pill splitting
14 April 2009
FDA panel backs limited use of Serdolect
8 April 2009
Stock Commentary - Europe - week to Aug 15
8 April 2009
FDA cardiac concerns on Lundbeck's Serdolect
7 April 2009
Stock Commentary - Europe - week to mar 30, 2009
2 April 2009
Takeda takes Lundbeck drugs into Ph I
30 March 2009
Elan shares leap on Lundbeck rumors
27 March 2009
Lunbeck expands rights to Biotie drug
23 March 2009
GTC Bio gains $1M ATryn milestone
16 March 2009
Lundbeck's 2008 net profit drops 15%
16 March 2009
Denmark's Lundbeck to buy Ovation for $900M
16 February 2009
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
